Tenet Healthcare reported a second quarter that outpaced both its own guidance and Wall Street expectations, pushing management to raise the company’s full-year outlook for 2026. The hospital and ambulatory surgery center operator posted $5.62 billion in revenues for Q2, about $180 million above consensus, with net income of $826 million (or $9.84 per diluted share). Adjusted EBITDA was $1.3 billion, and adjusted diluted earnings per share came in at $6.12, beating estimates by $1.86.
CEO Saum Sutaria, M.D., told analysts that the results reflect “the fundamental strength in our businesses” and set the basis for raising guidance after consecutive quarters of solid performance.
Tenet said it faced the same Affordable Care Act exchange-related challenges affecting many for-profit health systems, but overall business gains offset those pressures. Exchange-related patient revenues declined 17% year over year in Q2 and volumes decreased about 13.5%, creating an estimated $65 million headwind in the quarter. Executives noted that reduced exchange volumes have been converting into uninsured cases on a roughly one-to-one basis, a trend they expect to continue through the end of the year.
Despite that, other areas of the company grew: Tenet’s hospital segment recorded a 2.6% increase in same-facility inpatient adjusted admissions and a 3.3% gain in revenue per adjusted admission. Management attributed the revenue per admission improvement to higher acuity mix and an increase in supplemental Medicaid revenues, partially offset by the exchange decline.
CFO Sun Park highlighted that Q2 included $92 million of out-of-period Medicaid revenues tied to prior periods that were not part of the company’s initial 2026 guidance. Park added that the company would have posted a clean beat for the quarter even without those incremental Medicaid inflows.
Tenet’s ambulatory business, United Surgical Partners International (USPI), continued to contribute high-margin growth. As of the quarter’s close, the company had ownership interests in 538 ambulatory surgery centers and 26 surgical hospitals. USPI showed 5% same-facility revenue growth, net revenue per case rose 6.3%, and same-facility case volume dipped 1.2%, which management said reflected a focus on higher-acuity cases.
On the deal front, Sutaria said the company expects to exceed $300 million in full-year M&A spend for 2026 based on acquisitions closed so far and a robust pipeline. The planned acquisition activity is part of a strategy to expand ambulatory capacity and capture higher-margin surgical volume outside hospitals.
Executives described a mix of margin-improvement programs that supported results. Those included efficiency and productivity efforts, clinical operations work such as length-of-stay management, and technology investments focused on automation and artificial intelligence. Management said these measures — combined with revenue gains in several business lines — enabled Tenet to deliver a clean quarter despite enrollment uncertainty and payer mix shifts.
Following the strong first half and Q2 outperformance, Tenet raised its 2026 guidance. The company now expects revenues to be about $300 million higher and adjusted EBITDA roughly $295 million higher than prior guidance. Management said the adjusted EBITDA increase reflects $97 million of fundamental outperformance in the first half, an expected additional $58 million in the back half of the year, and $140 million more in supplemental Medicaid revenue.
The company also authorized a new $2 billion share repurchase program. Investors responded positively: Tenet’s shares were trading more than 20% above the open as of midday Friday.
Tenet’s ability to outpace the exchange-related pressures contrasts with some of its for-profit peers. The report cites Community Health Systems and HCA Healthcare as companies that have reported higher-than-expected uninsured volumes and have trimmed full-year guidance amid ongoing payer mix headwinds. Tenet executives said the company’s diversified performance across hospitals and ambulatory centers, plus Medicaid tailwinds and cost actions, helped it avoid the deeper hits seen elsewhere.
Company commentary and the guidance bump point to a few areas investors and industry watchers will likely follow through the rest of 2026:
Tenet’s quarterly release and analyst call framed the Q2 outcome as driven by broad operational gains across its hospital and ambulatory businesses, offsetting exchange-related enrollment weakness. Management signaled confidence in continued growth into the second half of 2026, though it acknowledged ongoing payer mix shifts and enrollment uncertainty as headwinds the company will monitor.
All financial figures, percentages and program amounts reported here derive from Tenet Healthcare’s Q2 2026 earnings release and the company’s public remarks on its analyst call as summarized in the source article. No additional data or outside projections were added.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.